

JASON SMITH, MD

Loma Linda Medical Center, Loma Linda, CA

Thrombolysis of the Main Portal Vein with EKOS®



Patient History

A 16-year-old male presented with severe epigastric pain to emergency department

- Abdominal CT demonstrated complete thrombosis of portal vein (PV), splenic vein (SV) and superior mesenteric veins (SMV)
- Patient started on pain control and heparin drip, and was admitted
- A hypercoagulable work-up was instituted, and interventional radiology (IR) was consulted

Initial Endovascular Treatment

- Heparin drip was held, and patient brought to IR
- Percutaneous trans-hepatic access obtained with US guidance into right PV, and a vascular sheath placed. A catheter was manipulated into patent middle colic vein; venogram confirmed SMV and PV thrombosis
- 3000 units of heparin administered intravenously and mechanical thrombectomy performed with Angiojet (Possis) from peripheral to central several times
- EKOS® (18 cm treatment length) device was placed across the SMV and main PV
- Through the right common femoral artery a diagnostic catheter placed with its tip in the superior mesenteric artery (SMA)
- 1mg/hour tPA infusions initiated in even split doses via EKOS and diagnostic catheters
- 300 units/hour heparin infusions initiated in even split doses via sheaths

Results

Patient brought back 21 hours after EKOS® placement:

- Recanalization of superior SMV and PV, but with residual scattered non-occlusive thrombus
- Balloon angioplasty performed of the SMA and main PV
- EKOS® device repositioned into SV, which remained thrombosed
- tPA and heparin infusions were continued overnight at same doses/rates
- Patient continued treatment with EKOS® overnight

Follow-up at 41 hours after EKOS® placement:

- Patient had hematuria overnight not requiring transfusion
- Completion angiograms demonstrated approximately 90% reduction in clot burden in portomesenteric veins, with robust hepatopetal flow
- Trans-hepatic sheath was removed and hemostasis achieved by tract embolization, and hemostasis was achieved at the groin puncture site with a percutaneous closure device placement.


Conclusion

- Lovenox therapy was begun. The patient's hematuria and pain resolved shortly thereafter
- Right upper quadrant Doppler ultrasound 4 days after completion of thrombolysis showed normal waveforms and widely patent hepatic, portal, and splenic vasculature
- Patient was discharged home later that day tolerating a normal diet and without pain


"EKOS® was an integral component in the efficient and thorough treatment of challenging extensive portomesenteric thrombus with prompt restoration of normal antegrade flow."

- Jason Smith, MD


Initial portal venogram



Initial EKOS® placement



Recanalization at 21 hour follow-up



Splenic arterial portogram at 41 hours



FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is indicated for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for Use, including warnings, precautions, potential complications, and contraindications can be found at www.ekoscorp.com. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. EKOS® and EkoSonic® are registered trademarks of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. © 2014 EKOS Corporation • US-EKO-2014-1526

EKOS CORPORATION
11911 N Creek Pkwy S.
Bothell, WA 98011